IXICO PLC (IXI) — Interim results for the six months ended 31 March 2025

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the IXICO PLC Interim Results Investor Presentation. Throughout the quarter presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time by the Q and A tab situated in the right corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives from the meeting itself, however the company can review all the questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you to CEO, Graham Gordon. Good afternoon to you, sir. Well, thank you very much, and and welcome, everyone. Delighted to be presenting the h one interim results for 2025, which are, as you may remember, the first for me. Started as CEO summer last year. Obviously, Grant is a somewhat more familiar face to you, I think, with our CFO and and recently also promoted to chief operating officer. So with that, let's dive into this. I wanted to remind everyone of who we are and what we do, just to make sure that we set the scene correctly. You see us actually using a somewhat different language maybe than what has been seen before, Precision in neuroscience because that is very much who we are. So we, run an AI driven technology, a platform that does analytics of neurological clinical trials. And behind that is, of course, an entire team also that helps with the end to end analysis of these, of these data. So if you look at us at a glance, as I just mentioned, that the one hand, an AI driven platform, basically is a backbone, which we call trial tracker that then is equipped with algorithms, with biomarker algorithms, and we'll come back to that because they're...